Keyphrases
Farnesylthiosalicylic Acid
100%
Celecoxib
100%
Anti-inflammatory Effect
100%
Prostaglandin E2
100%
T-cell Mediated
100%
Inflammatory Disorders
50%
Clinical Trials
25%
Lymphocytes
25%
Inhibitory Effect
25%
High-risk Population
25%
Combined Treatment
25%
Salirasib
25%
Anti-inflammatory Activity
25%
Cyclooxygenase-2 Inhibitors
25%
Lymphocyte Cell
25%
Ras Activation
25%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
25%
Mast Cells
25%
Arthritis
25%
Interleukin-2
25%
Oncogenic Ras
25%
ERK Phosphorylation
25%
Lymphocyte Adhesion
25%
Colon Polyps
25%
Antiproliferative Properties
25%
Celebrex
25%
Immunology and Microbiology
Lymphocyte
100%
T Cell
100%
Antiinflammatory Activity
100%
Prostaglandin E2
100%
Inflammatory Disorder
66%
Secretion (Process)
66%
Colon
33%
Awareness
33%
Arthritis
33%
High Risk Population
33%
Mast Cell
33%
Interleukin 2
33%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Antiinflammatory Activity
100%
Prostaglandin E2
100%
Celecoxib
100%
Lymphocyte
75%
Secretion (Process)
50%
Colon
25%
High Risk Population
25%
Awareness
25%
Clinical Trial
25%
Interleukin 2
25%
Mast Cell
25%
COX-2 Inhibitor
25%
Pharmacology, Toxicology and Pharmaceutical Science
Salirasib
100%
Celecoxib
100%
Antiinflammatory Activity
100%
Prostaglandin E2
100%
Disease
40%
Clinical Trial
20%
COX-2 Inhibitor
20%
Non-Steroidal Anti-Inflammatory Drug
20%
Arthritis
20%
Interleukin 2
20%
Colon Polyp
20%